DOCSLIB.ORG

Title Authors Affiliations Abstract

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Title Authors Affiliations Abstract bioRxiv preprint doi: https://doi.org/10.1101/2021.06.12.448188; this version posted June 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Title 2 Pharmacologic and genetic inhibition of cholesterol esterification reduces tumour burden: a 3 pan-cancer systematic review and meta-analysis of preclinical models 4 Authors 5 Alex Websdale1, Yi Kiew1,$, Philip Chalmers1,$, Xinyu Chen1, Giorgia Cioccoloni1, Thomas A 6 Hughes2, Xinyu Luo1, Rufaro Mwarzi1, Marc Poirot3, Hanne Røberg-Larsen4, Ruoying Wu1, 7 Mengfan Xu1, Michael A. Zulyniak1 and James L Thorne1,€. 8 Affiliations 9 1School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT, UK. 10 2School of Medicine, University of Leeds, Leeds, LS9 7TF, UK 11 3Cancer Research Center of Toulouse, Inserm, CNRS, University of Toulouse, Toulouse, France 12 4Department of Chemistry, University of Oslo, Norway 13 $These authors contributed equally 14 €Corresponding author [email protected] 15 16 Abstract 17 Cholesterol esterification proteins Sterol-O acyltransferases (SOAT) 1 and 2 are emerging 18 prognostic markers in many cancers. These enzymes utilise fatty acids conjugated to 19 coenzyme A to esterify cholesterol. Cholesterol esterification is tightly regulated and enables 20 formation of lipid droplets that act as storage organelles for lipid soluble vitamins and 21 minerals, and as cholesterol reservoirs. In cancer, this provides rapid access to cholesterol to 22 maintain continual synthesis of the plasma membrane. In this systematic review and meta- bioRxiv preprint doi: https://doi.org/10.1101/2021.06.12.448188; this version posted June 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 23 analysis, we summarise the current depth of understanding of the role of this metabolic 24 pathway in pan-cancer development. A systematic search of PubMed, Scopus, and Web of 25 Science for preclinical studies identified eight studies where cholesteryl ester concentrations 26 were compared between tumour and adjacent-normal tissue, and 24 studies where 27 cholesterol esterification was blocked by pharmacological or genetic approaches. Tumour 28 tissue had a significantly greater concentration of cholesteryl esters than non-tumour tissue 29 (p<0.0001). Pharmacological or genetic inhibition of SOAT was associated with significantly 30 smaller tumours of all types (p≤0.002). SOAT inhibition increased tumour apoptosis 31 (p=0.007), CD8+ lymphocyte infiltration and cytotoxicity (p≤0.05), and reduced proliferation 32 (p=0.0003) and metastasis (p<0.0001). Significant risk of publication bias was found and may 33 have contributed to a 32% overestimation of the meta-analysed effect size was 34 overestimated. Avasimibe, the most frequently used SOAT inhibitor, was effective at doses 35 equivalent to those previously reported to be safe and tolerable in humans. This work 36 indicates that SOAT inhibition should be explored in clinical trials as an adjunct to existing 37 anti-neoplastic agents. 38 1. Introduction 39 Esterification is a tightly regulated component of cholesterol homeostasis and enables 40 cholesterol packaging into lipid droplets. Intra-cellular storage of cholesterol allows ready 41 access to meet the high demand for de novo plasma membrane synthesis during the rapid 42 proliferation of cells, for example during tumour growth. Several diseases are linked to 43 cholesterol esterification including a range of neurological conditions, lipid disorders, and 44 cancer. The synthesis of cholesteryl esters (CE) is catalysed by Sterol O-acyltransferase 1 and 45 2 (SOAT1 and SOAT2), and Lecithin cholesterol acyltransferase (LCAT). SOAT1 and SOAT2, 46 utilise fatty acid-coenzyme A conjugates to preferentially generate oleoyl (Fig1A), and 47 linoleoyl or palmitoyl CEs (Fig1B), respectively, and coenzyme A as a biproduct [1]. LCAT 48 utilises phosphatidylcholine (lecithin) to produce oleoyl CEs [2] but instead of producing 49 coenzyme A as a biproduct, as is the case for SOAT1 and SOAT2, lysophosphatidylcholine is 50 the biproduct (Fig1C). SOAT1 is ubiquitously expressed in tissues while SOAT2 is restricted to 51 small intestines and the liver [3] and LCAT is expressed in the liver and secreted into 52 circulation in lipoprotein complexes [4, 5]. bioRxiv preprint doi: https://doi.org/10.1101/2021.06.12.448188; this version posted June 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 53 Esterification of cholesterol in tumours is beneficial for cancer growth and studies of SOAT1, 54 SOAT2 and LCAT in humans indicate this metabolic process is deregulated in cancer. Elevated 55 SOAT1 and SOAT2 expression in tumours has been linked to higher grade of breast [6] and 56 renal [7] cancer, respectively, and high expression SOAT1 has also been linked to poor 57 prognosis for patients with liver [8], glioma [9], pancreatic [10] and adrenocortical [11] 58 cancers. Furthermore, increased intracellular lipid droplet content, indicative of cholesterol 59 esterification, is associated with reduced overall survival [12] and elevated cholesteryl oleoyl 60 ester levels has been proposed as a prognostic biomarker for prostate cancer [13]. 61 Conversely, high LCAT expression is associated with improved prognosis for liver cancer 62 patients [14] and is often lower in liver cancer than normal tissue in humans [15] and rat 63 models [16-18]. At the molecular level, cholesteryl esters promote cancer proliferation and 64 invasiveness [19] and thus SOATs were considered as promising targets and the anticancer 65 action of natural SOAT inhibitors such as auraptene and bryonolic acid was elucidated [20, 66 21]. Several small molecule inhibitors of cholesterol esterification have been explored in 67 clinical trials for non-cancer related diseases providing an extensive understanding of their 68 tolerability, toxicity and side-effect profiles. Avasimibe, first discovered in 1996 [22], is a dual 69 SOAT1 and SOAT2 inhibitor [23, 24] and has been used in clinical trials for coronary 70 atherosclerosis [25] and homozygous familial hypercholesterolemia [26]. Avasimin is human 71 serum albumin encapsulated avasimibe that was developed to improve avasimibe solubility 72 [27]. K-604 is a SOAT1 specific inhibitor [24] and has been tested for both safety and efficacy 73 as a treatment against atherosclerosis (NCT00851500), however results from the trial have 74 not been published. ATR-101 (Nevanimibe) is a SOAT1 specific inhibitor [28] that has been 75 tested in a clinical trial against adrenocortical carcinoma (NCT01898715) [29] and Cushing’s 76 syndrome (NCT03053271). Pactimibe also inhibits both SOAT1 and SOAT2 [23, 30], but a 77 clinical trial (NCT00151788) administering 100 mg/day was terminated early due to a 78 significant increase in major cardiovascular disease events [31]; pactimibe remains untested 79 in pre-clinical cancer models. Drugs targeting CE synthesis that have been evaluated in clinical 80 trials are summarised in Table 1. 81 There is a significant body of research investigating cholesterol esterification in pre-clinical 82 cancer models. Many of these studies utilise pharmacological or genetic inhibitors of SOAT to 83 provide insight into the cellular and molecular role of the enzyme and propose repurposing bioRxiv preprint doi: https://doi.org/10.1101/2021.06.12.448188; this version posted June 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 84 SOAT inhibitors as cancer therapies. However, the pharmacological compounds remain 85 underexplored in the clinical cancer setting and may be suitable for repurposing. This 86 systematic review and meta-analysis summarises the evidence regarding cholesterol 87 esterification enzymes as therapeutic targets in cancer and details the range of 88 pharmacological approaches that are closest to clinical translation. 89 2. Methods 90 2.1 Search strategy 91 The search strategy was applied to PubMed, SCOPUS, Web of Science and the Cochrane 92 Library, and records were retrieved up until April 2021; the strategy is registered in the 93 PROSPERO database (CRD42020202409) with the following modifications: records evaluating 94 sulfation and associated enzymes were excluded from the study. 95 2.2 Study selection 96 Titles and abstracts were screened against inclusion criteria; (i) original research, (ii) 97 investigated cancer, (iii) assessed an in vivo pre-clinical animal model and (iv) modulated 98 cholesterol esterification. Each abstract was assessed by two independent assessors and 99 discrepancies resolved by a third member of the research team. All publications that satisfied 100 the above criteria were included for qualitative assessment. 101 2.3 Data extraction 102 Publication that reported adequate data for quantitative assessment were included in the 103
Load more

Recommended publications
  • SOAT1 Polyclonal Antibody
    PRODUCT DATA SHEET Bioworld Technology,Inc. SOAT1 polyclonal antibody Catalog: BS8121 Host: Rabbit Reactivity: Human,Mouse,Rat BackGround: Purification&Purity: SOAT1 (sterol O-acyltransferase-1), also designated The antibody was affinity-purified from rabbit antiserum ACAT1, is a homotetra-meric enzyme that catalyzes the by affinity-chromatography using epitope-specific im- formation of cholesterol esters from cholesterol and long munogen and the purity is > 95% (by SDS-PAGE). chain fatty acyl-coenzyme A (acyl-CoA). The gene en- Applications: coding human SOAT1 maps to chromosome 1 and is ex- WB 1:500 - 1:2000 pressed as a protein that localizes to the endoplasmic re- Storage&Stability: ticulum (ER) in several tissues, including liver, kidney, Store at 4°C short term. Aliquot and store at -20°C long adrenal glands and macrophages. SOAT1 is involved in term. Avoid freeze-thaw cycles. cellular cholesterol homeostasis as well as in foam cell Specificity: formation and the subsequent progression of atheroscle- SOAT1 polyclonal antibody detects endogenous levels of rosis. Several SOAT inhibitors have been developed for SOAT1 protein. the treatment of atherosclerosis. SOAT2 (sterol DATA: O-acyltransferase-2), also known as ACAT2 (acyl-CoA:cholesterol acyltransferase-2), participates in lipo-protein assembly, catalyzing cholesterol esterifica- tion in mammalian cells. SOAT2 is an integral membrane protein that localizes to the endoplasmic reticulum of human intestinal cells. SOAT2 deficiency contributes to severe mental retardation and hypotonus. Product: WesternBlot (WB) analysis of SOAT1 polyclonal antibody Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, Note: 50% glycerol, pH7.2 For research use only, not for use in diagnostic procedure.
    [Show full text]
  • ACAT) in Cholesterol Metabolism: from Its Discovery to Clinical Trials and the Genomics Era
    H OH metabolites OH Review Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its Discovery to Clinical Trials and the Genomics Era Qimin Hai and Jonathan D. Smith * Department of Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH 44195, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-216-444-2248 Abstract: The purification and cloning of the acyl-coenzyme A: cholesterol acyltransferase (ACAT) enzymes and the sterol O-acyltransferase (SOAT) genes has opened new areas of interest in cholesterol metabolism given their profound effects on foam cell biology and intestinal lipid absorption. The generation of mouse models deficient in Soat1 or Soat2 confirmed the importance of their gene products on cholesterol esterification and lipoprotein physiology. Although these studies supported clinical trials which used non-selective ACAT inhibitors, these trials did not report benefits, and one showed an increased risk. Early genetic studies have implicated common variants in both genes with human traits, including lipoprotein levels, coronary artery disease, and Alzheimer’s disease; however, modern genome-wide association studies have not replicated these associations. In contrast, the common SOAT1 variants are most reproducibly associated with testosterone levels. Keywords: cholesterol esterification; atherosclerosis; ACAT; SOAT; inhibitors; clinical trial Citation: Hai, Q.; Smith, J.D. Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its 1. Introduction Discovery to Clinical Trials and the The acyl-coenzyme A:cholesterol acyltransferase (ACAT; EC 2.3.1.26) enzyme family Genomics Era. Metabolites 2021, 11, consists of membrane-spanning proteins, which are primarily located in the endoplasmic 543. https://doi.org/10.3390/ reticulum [1].
    [Show full text]
  • Role of De Novo Cholesterol Synthesis Enzymes in Cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2
    Journal of Cancer 2020, Vol. 11 1761 Ivyspring International Publisher Journal of Cancer 2020; 11(7): 1761-1767. doi: 10.7150/jca.38598 Review Role of de novo cholesterol synthesis enzymes in cancer Jie Yang1,2, Lihua Wang1,2, Renbing Jia1,2 1. Department of Ophthalmology, Ninth People’s Hospital of Shanghai, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China. Corresponding authors: Renbing Jia, [email protected] and Lihua Wang, [email protected]. Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, No. 639 Zhi Zao Ju Road, Shanghai 200011, China © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.07.21; Accepted: 2019.11.30; Published: 2020.01.17 Abstract Despite extensive research in the cancer field, cancer remains one of the most prevalent diseases. There is an urgent need to identify specific targets that are safe and effective for the treatment of cancer. In recent years, cancer metabolism has come into the spotlight in cancer research. Lipid metabolism, especially cholesterol metabolism, plays a critical role in membrane synthesis as well as lipid signaling in cancer. This review focuses on the contribution of the de novo cholesterol synthesis pathway to tumorigenesis, cancer progression and metastasis. In conclusion, cholesterol metabolism could be an effective target for novel anticancer treatment. Key words: metabolic reprogramming, de novo cholesterol synthesis, cancer progress Introduction Over the past few decades, numerous published that cholesterol plays a critical role in cancer studies have focused on cancer cell metabolism and progression15-19.
    [Show full text]
  • For Poststroke Depression Based on Network Pharmacology and Molecular Docking
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2021, Article ID 2126967, 14 pages https://doi.org/10.1155/2021/2126967 Research Article Exploring the Mechanism of Action of Herbal Medicine (Gan-Mai-Da-Zao Decoction) for Poststroke Depression Based on Network Pharmacology and Molecular Docking Zhicong Ding ,1 Fangfang Xu,1 Qidi Sun,2 Bin Li,1 Nengxing Liang,1 Junwei Chen,1 and Shangzhen Yu 1,3 1Jinan University, Guangzhou 510632, China 2Yangzhou University, Yangzhou 225009, China 3Wuyi Hospital of Traditional Chinese Medicine, Jiangmen 529000, China Correspondence should be addressed to Shangzhen Yu; [email protected] Received 19 May 2021; Accepted 14 August 2021; Published 23 August 2021 Academic Editor: Ghulam Ashraf Copyright © 2021 Zhicong Ding et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Poststroke depression (PSD) is the most common and serious neuropsychiatric complication occurring after ce- rebrovascular accidents, seriously endangering human health while also imposing a heavy burden on society. Nevertheless, it is difficult to control disease progression. Gan-Mai-Da-Zao Decoction (GMDZD) is effective for PSD, but its mechanism of action in PSD is unknown. In this study, we explored the mechanism of action of GMDZD in PSD treatment using network pharmacology and molecular docking. Material and methods. We obtained the active components of all drugs and their targets from the public database TCMSP and published articles. -en, we collected PSD-related targets from the GeneCards and OMIM databases.
    [Show full text]
  • The Molecular Biology of Pancreatic Adenocarcinoma: Translational Challenges and Clinical Perspectives
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives Shun Wang1, Yan Zheng1, Feng Yang2, Le Zhu1, Xiao-Qiang Zhu3, Zhe-Fang Wang4, Xiao-Lin Wu4, Cheng-Hui Zhou4, Jia-Yan Yan4,5, Bei-Yuan Hu1, Bo Kong6, De-Liang Fu2, Christiane Bruns4, Yue Zhao4, Lun-Xiu Qin1 and Qiong-Zhu Dong 1,7 Pancreatic cancer is an increasingly common cause of cancer mortality with a tight correspondence between disease mortality and incidence. Furthermore, it is usually diagnosed at an advanced stage with a very dismal prognosis. Due to the high heterogeneity, metabolic reprogramming, and dense stromal environment associated with pancreatic cancer, patients benefit little from current conventional therapy. Recent insight into the biology and genetics of pancreatic cancer has supported its molecular classification, thus expanding clinical therapeutic options. In this review, we summarize how the biological features of pancreatic cancer and its metabolic reprogramming as well as the tumor microenvironment regulate its development and progression. We further discuss potential biomarkers for pancreatic cancer diagnosis, prediction, and surveillance based on novel liquid biopsies. We also outline recent advances in defining pancreatic cancer subtypes and subtype-specific therapeutic responses and current preclinical therapeutic models. Finally, we discuss prospects and challenges in the clinical development of pancreatic cancer therapeutics.
    [Show full text]
  • The Interplay Between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina
    biomolecules Article The Interplay between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina Alexey M. Petrov , Artem A. Astafev, Natalia Mast, Aicha Saadane, Nicole El-Darzi and Irina A. Pikuleva * Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH 44106, USA; [email protected] (A.M.P.); [email protected] (A.A.A.); [email protected] (N.M.); [email protected] (A.S.); [email protected] (N.E.-D.) * Correspondence: [email protected]; Tel.: +1-216-368-3823 Received: 13 November 2019; Accepted: 10 December 2019; Published: 12 December 2019 Abstract: In mammalian retina, cholesterol excess is mainly metabolized to oxysterols by cytochromes P450 27A1 (CYP27A1) and 46A1 (CYP46A1) or removed on lipoprotein particles containing apolipoprotein E (APOE). In contrast, esterification by sterol-O-acyltransferase 1 (SOAT) plays only a minor role in this process. Accordingly, retinal cholesterol levels are unchanged / / / / in Soat1− − mice but are increased in Cyp27a1− −Cyp46a1− − and Apoe− − mice. Herein, we / / / / / / characterized Cyp27a1− −Cyp46a1− −Soat1− − and Cyp27a1− −Cyp46a1− −Apoe− − mice. In the former, retinal cholesterol levels, anatomical gross structure, and vasculature were normal, yet the / / / electroretinographic responses were impaired. Conversely, in Cyp27a1− −Cyp46a1− −Apoe− − mice, retinal cholesterol levels were increased while anatomical structure and vasculature were unaffected with only male mice showing a decrease in electroretinographic responses. Sterol profiling, qRT-PCR, proteomics, and transmission electron microscopy mapped potential compensatory mechanisms / / / / / / in the Cyp27a1− −Cyp46a1− −Soat1− − and Cyp27a1− −Cyp46a1− −Apoe− − retina. These included decreased cholesterol biosynthesis along with enhanced formation of intra- and extracellular vesicles, possibly a reserve mechanism for lowering retinal cholesterol.
    [Show full text]
  • Inhibition Mechanism of Human Sterol O-Acyltransferase 1 by Competitive Inhibitor
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.07.897124; this version posted January 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 2 Inhibition mechanism of human sterol O-acyltransferase 1 by competitive inhibitor 3 4 Chengcheng Guan1, Yange Niu1, Si-Cong Chen2, Yunlu Kang1, Jing-Xiang Wu1, 5 Koji Nishi3, Catherine C. Y. Chang3, Ta-Yuan Chang3, Tuoping Luo 2,4,5 Lei Chen 1,4,5 6 1 State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, Peking 7 University, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Beijing 100871, 8 China 9 2 Key Laboratory of Bioorganic Chemistry and Molecular Engineering, Ministry of Education 10 and Beijing National Laboratory for Molecular Science, College of Chemistry and Molecular 11 Engineering, Peking University, Beijing 100871, China, 12 3 Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, 13 Hanover, NH 03755, USA 14 4 Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China 15 5Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China 16 *Correspondence: Lei Chen, [email protected] 17 18 19 20 21 22 23 bioRxiv preprint doi: https://doi.org/10.1101/2020.01.07.897124; this version posted January 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • SOAT1 Promotes Mevalonate Pathway Dependency in Pancreatic Cancer
    ARTICLE SOAT1 promotes mevalonate pathway dependency in pancreatic cancer Tobiloba E. Oni1,2,3*, Giulia Biffi1,2,4*, Lindsey A. Baker1,2**,YuanHao1**, Claudia Tonelli1,2, Tim D.D. Somerville1,AstridDeschenesˆ 1,2, Pascal Belleau1,Chang-ilHwang1,2,5, Francisco J. Sanchez-Rivera´ 6, Hilary Cox1,ErinBrosnan1,2, Abhishek Doshi1,2, Rebecca P. Lumia1,2, Kimia Khaledi1,2, Youngkyu Park1,2, Lloyd C. Trotman1, Scott W. Lowe6,7, Alexander Krasnitz1, Christopher R. Vakoc1, and David A. Tuveson1,2 Downloaded from http://rupress.org/jem/article-pdf/217/9/e20192389/1046931/jem_20192389.pdf by University Of California, Davis user on 01 September 2020 Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, and new therapies are needed. Altered metabolism is a cancer vulnerability, and several metabolic pathways have been shown to promote PDAC. However, the changes in cholesterol metabolism and their role during PDAC progression remain largely unknown. Here we used organoid and mouse models to determine the drivers of altered cholesterol metabolism in PDAC and the consequences of its disruption on tumor progression. We identified sterol O-acyltransferase 1 (SOAT1) as a key player in sustaining the mevalonate pathway by converting cholesterol to inert cholesterol esters, thereby preventing the negative feedback elicited by unesterified cholesterol. Genetic targeting of Soat1 impairs cell proliferation in vitro and tumor progression in vivo and reveals a mevalonate pathway dependency in p53 mutant PDAC cells that have undergone p53 loss of heterozygosity (LOH). In contrast, pancreatic organoids lacking p53 mutation and p53 LOH are insensitive to SOAT1 loss, indicating a potential therapeutic window for inhibiting SOAT1 in PDAC.
    [Show full text]
  • A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture
    ORIGINAL RESEARCH published: 06 July 2021 doi: 10.3389/fgene.2021.639858 A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture Xin-Xin Han1*†, Chunhui Cai2†, Li-Ming Yu1, Min Wang3, Dai-Yu Hu2, Jie Ren2, Meng-Han Zhang1, Lu-Ying Zhu1, Wei-Hua Zhang1, Wei Huang1, Hua He4,5* and Zhengliang Gao2* Edited by: Helen He Zhu, 1 Shanghai Key Laboratory of Craniomaxillofacial Development and Diseases, Shanghai Stomatological Hospital, Fudan Shanghai Jiao University, Shanghai, China, 2 Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine, Tongji Tong University, China University, Shanghai, China, 3 School of Medicine, Jiaxing University, Jiaxing, China, 4 Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, China, 5 Department of Neurosurgery, Third Affiliated Reviewed by: Jianwei Jiao, Hospital of Second Military Medical University, Shanghai, China Institute of Zoology, Chinese Academy of Sciences, China Glioma is the most common and malignant primary brain tumor. Patients with malignant Pengcheng Zhang, Shanghai Institute of Materia Medica, glioma usually have a poor prognosis due to drug resistance and disease relapse. Chinese Academy of Sciences, China Cancer stem cells contribute to glioma initiation, progression, resistance, and relapse. *Correspondence: Hence, quick identification and efficient understanding of glioma stem cells (GSCs) are Xin-Xin Han [email protected] of profound importance for therapeutic strategies and outcomes. Ideally, therapeutic Hua He approaches will only kill cancer stem cells without harming normal neural stem cells [email protected] (NSCs) that can inhibit GSCs and are often beneficial. It is key to identify the differences Zhengliang Gao [email protected] between cancer stem cells and normal NSCs.
    [Show full text]
  • Quantitative Trait Loci Mapping of Macrophage Atherogenic Phenotypes
    QUANTITATIVE TRAIT LOCI MAPPING OF MACROPHAGE ATHEROGENIC PHENOTYPES BRIAN RITCHEY Bachelor of Science Biochemistry John Carroll University May 2009 submitted in partial fulfillment of requirements for the degree DOCTOR OF PHILOSOPHY IN CLINICAL AND BIOANALYTICAL CHEMISTRY at the CLEVELAND STATE UNIVERSITY December 2017 We hereby approve this thesis/dissertation for Brian Ritchey Candidate for the Doctor of Philosophy in Clinical-Bioanalytical Chemistry degree for the Department of Chemistry and the CLEVELAND STATE UNIVERSITY College of Graduate Studies by ______________________________ Date: _________ Dissertation Chairperson, Johnathan D. Smith, PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, David J. Anderson, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Baochuan Guo, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Stanley L. Hazen, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Renliang Zhang, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Aimin Zhou, PhD Department of Chemistry, Cleveland State University Date of Defense: October 23, 2017 DEDICATION I dedicate this work to my entire family. In particular, my brother Greg Ritchey, and most especially my father Dr. Michael Ritchey, without whose support none of this work would be possible. I am forever grateful to you for your devotion to me and our family. You are an eternal inspiration that will fuel me for the remainder of my life. I am extraordinarily lucky to have grown up in the family I did, which I will never forget.
    [Show full text]
  • Identification of Soat1 As a Quantitative Trait Locus Gene on Mouse Chromosome 1 Contributing to Hyperlipidemia
    Identification of Soat1 as a Quantitative Trait Locus Gene on Mouse Chromosome 1 Contributing to Hyperlipidemia Zongji Lu1., Zuobiao Yuan1., Toru Miyoshi1, Qian Wang1, Zhiguang Su1, Catherine C. Chang3, Weibin Shi1,2* 1 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia, United States of America, 2 Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, United States of America, 3 Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire, United States of America Abstract We previously identified two closely linked quantitative trait loci (QTL) on distal chromosome 1 contributing to major variations in plasma cholesterol and triglyceride levels in an intercross derived from C57BL/6 (B6) and C3H/HeJ (C3H) apolipoprotein E-deficient (apoE2/2) mice. Soat1, encoding sterol o-acyltransferase 1, is a functional candidate gene located underneath the proximal linkage peak. We sequenced the coding region of Soat1 and identified four single nucleotide polymorphisms (SNPs) between B6 and C3H mice. Two of the SNPs resulted in amino-acid substitutions (Ile147Val and His205Tyr). Functional assay revealed an increased enzyme activity of Soat1 in peritoneal macrophages of C3H mice relative to those of B6 mice despite comparable protein expression levels. Allelic variants of Soat1 were associated with variations in plasma cholesterol and triglyceride levels in an intercross between B6.apoE2/2 and C3H.apoE2/2 mice. Inheritance of the C3H allele resulted in significantly higher plasma lipid levels than inheritance of the B6 allele. Soat1 variants were also significantly linked to major variations in plasma esterified cholesterol levels but not with free cholesterol levels. Trangenic expression of C3H Soat1 in B6.apoE2/2 mice resulted in elevations of plasma cholesterol and triglyceride levels.
    [Show full text]
  • 198.Guan C, Niu Y, Chen S C, Et Al. Structural Insights Into the Inhibition
    ARTICLE https://doi.org/10.1038/s41467-020-16288-4 OPEN Structural insights into the inhibition mechanism of human sterol O-acyltransferase 1 by a competitive inhibitor Chengcheng Guan1, Yange Niu1, Si-Cong Chen2, Yunlu Kang1, Jing-Xiang Wu1, Koji Nishi3, ✉ Catherine C. Y. Chang 3, Ta-Yuan Chang3, Tuoping Luo 2,4,5 & Lei Chen 1,4,5 O 1234567890():,; Sterol -acyltransferase 1 (SOAT1) is an endoplasmic reticulum (ER) resident, multi- transmembrane enzyme that belongs to the membrane-bound O-acyltransferase (MBOAT) family. It catalyzes the esterification of cholesterol to generate cholesteryl esters for cho- lesterol storage. SOAT1 is a target to treat several human diseases. However, its structure and mechanism remain elusive since its discovery. Here, we report the structure of human SOAT1 (hSOAT1) determined by cryo-EM. hSOAT1 is a tetramer consisted of a dimer of dimer. The structure of hSOAT1 dimer at 3.5 Å resolution reveals that a small molecule inhibitor CI-976 binds inside the catalytic chamber and blocks the accessibility of the active site residues H460, N421 and W420. Our results pave the way for future mechanistic study and rational drug design targeting hSOAT1 and other mammalian MBOAT family members. 1 State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, Peking University, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, 100871 Beijing, China. 2 Key Laboratory of Bioorganic Chemistry and Molecular Engineering, Ministry of Education and Beijing National Laboratory for Molecular Science, College of Chemistry and Molecular Engineering, Peking University, 100871 Beijing, China. 3 Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
    [Show full text]